IRCT20200407046981N50尚未招募未知
Comparative bioequivalence study of the Desloratadine 5-mg Tablets manufactured by Behestan Pharmaceutical Company with Desloratadine brand tablets (Clarinex® ) by Organon company
Behestan Pharmaceutical Company0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- Male
入选标准
- •The weight limit of each volunteer should be between 60 and 100 kg.
- •All volunteers must be non-smokers.
- •They must be healthy in terms of liver, kidney, respiratory system, mental and other general health characteristics that will be assessed.
- •Candidates who have consented to the consent form
排除标准
- •Known hypersensitivity or idiosyncratic reaction to Desloratadine or any ingredients.
- •Subjects with BP = 90/60 mm/Hg or BP = 140/90 mm/Hg.
- •Taking any medicine during two week before dosing.
研究者
相似试验
尚未招募
不适用
Comparative in vivo evaluation of 2 Desloratadine 5 mg Tablet formulations.IRCT20180620040164N40Darou darman Pars Co.24
尚未招募
Unknown
Comparative in vivo evaluation of 2 Desloratadine 5 mg Tablet formulations.IRCT20180620040164N60Actover Pharmaceutical Co.24
尚未招募
Unknown
Comparative in vivo evaluation of 2 Desloratadine 5 mg Tablet formulations.IRCT20180620040164N61Darou darman Arang24
已完成
Unknown
Bioequivalence Study of desloratadine 5 mg manufactured by Pharma Chemi and Clarinex manufactured by ScheringIRCT20220209053979N7Pharmachemi Company24
尚未招募
不适用
Study of absorption and elimination rate of Domperidone suspension 1 mg/ml in comparison with Domperidone brand suspension (Motilium®).IRCT20200407046981N35ona Darou Pars Pharmaceutical Company24